3 results
To assess if treatment of an intermediate vulnerable coronary lesion in symptomatic patients using a BVS is feasible, results in a more stable plaque, increases vessel luminal area, preserves or improves vasomotion and is not associated with…
To evaluate if an individualized antithrombotic P2Y12-inhibitor monotherapy in comparison to an individualized DAPT treatment is superior regarding bleeding events and non-inferior regarding ischemic events in patient with CCS after PCI.
Valemetostat tosylate may modify epigenetic changes, which plays an important role in the pathogenesis of PTCL. In the ongoing open-label Phase 1 study (DS3201-A-J101, 25 Dec 2019 data cut-off), valemetostat tosylate monotherapy demonstrated…